

# Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology and Market Forecast 2028

<https://marketpublishers.com/r/A984411E96FEN.html>

Date: June 2019

Pages: 95

Price: US\$ 5,980.00 (Single User License)

ID: A984411E96FEN

## Abstracts

### REPORT SUMMARY

'Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology and Market Forecast 2028' report provides the detailed overview of the disease and in depth understanding of historical and forecasted epidemiology. It highlights the existing treatment patterns, potential upcoming drugs and also identifies best of the market opportunities by providing the current and forecasted market revenue, sales trends, and drug uptake during the study period from 2016-2028.

Market Segment by Countries, covering?

United States

EU5 (Germany, France, Italy, Spain and the United Kingdom)

Japan

Study Period: 2016-2028

Amyotrophic lateral sclerosis (ALS) Understanding and Treatment Algorithm

The report provides the in depth analysis of the disease overview by providing details such as disease definition, classification, symptoms, etiology, pathophysiology and diagnostic trends. The comprehensive details about treatment algorithms and treatment guidelines for Amyotrophic lateral sclerosis (ALS) in the US, Europe, and Japan are also provided in the report.

Amyotrophic lateral sclerosis (ALS) Epidemiology

This section provide the insights about historical and current patient pool and forecasted trend for 7 major markets. It takes in to account the analysis of numerous studies,

survey reports as well as KOL's views which helps to recognize the factors behind the current and forecasted trends, diagnosed and treatable patient pool along with assumptions undertaken.

#### Amyotrophic lateral sclerosis (ALS) Product Profiles & Analysis

This part of the Amyotrophic lateral sclerosis (ALS) report encloses the detailed analysis of marketed drugs and Phase III and late Phase II pipeline drugs. It provides the key cross competition which evaluates the drugs on several parameters including, safety & efficacy results, mechanism of action, route, launch dates and designations. This section also covers the market intelligence and tracking of latest happenings, agreements and collaborations, approvals, patent details and other major breakthroughs.

#### Amyotrophic lateral sclerosis (ALS) Market Outlook

The Amyotrophic lateral sclerosis (ALS) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment analyses the market trend of each marketed drug and late-stage pipeline drugs. This is done by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders . The calculated market data is presented with relevant tables and graphs to give a clear view of the market at first sight.

#### Amyotrophic lateral sclerosis (ALS) Market Share by Therapies

This section focusses on the rate of uptake of the potential drugs recently launched or will be launched in the market during the study period from 2016-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This information also helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs. It provides the comparison of the drugs on the basis of market share and size. This analysis helps in investigating factors important in market uptake and in making financial as well as regulatory decisions.

#### Amyotrophic lateral sclerosis (ALS) Report Insights

Patient Population in Amyotrophic lateral sclerosis (ALS)

Therapeutic Approaches in Amyotrophic lateral sclerosis (ALS)

Amyotrophic lateral sclerosis (ALS) Pipeline Analysis

Amyotrophic lateral sclerosis (ALS) Market Size and Trends  
Amyotrophic lateral sclerosis (ALS) Market Opportunities  
Impact of upcoming Therapies in Amyotrophic lateral sclerosis (ALS)

Amyotrophic lateral sclerosis (ALS) Report Key Strengths  
10 Year Forecast  
7MM Coverage  
Epidemiology Segmentation  
Drugs Uptake  
Highly Analyzed Market  
Key Cross Competition

Amyotrophic lateral sclerosis (ALS) Report Assessment  
Current Treatment Practices in Amyotrophic lateral sclerosis (ALS)  
Unmet Needs in Amyotrophic lateral sclerosis (ALS)  
Detailed Amyotrophic lateral sclerosis (ALS) Pipeline Product Profiles  
Market Attractiveness  
Market Drivers and Barriers

Key Benefits

This report will help to develop Business Strategies by understanding the trends shaping and driving the Amyotrophic lateral sclerosis (ALS) market  
Organize sales and marketing efforts by identifying the best opportunities for Amyotrophic lateral sclerosis (ALS) market  
To understand the future market competition in the Amyotrophic lateral sclerosis (ALS) market.

**Note:** We understand the needs of the rapidly changing market and is helping the client by providing the most up to date Report. It usually takes 4-5 days to deliver this kind of Report. The report coverage will depend on the availability of the data.  
Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

## Contents

### **1 KEY INSIGHTS**

### **2 AMYOTROPHIC LATERAL SCLEROSIS (ALS) MARKET OVERVIEW AT A GLANCE**

- 2.1 Market Share (%) Distribution of Amyotrophic lateral sclerosis (ALS) in 2018
- 2.2 Market Share (%) Distribution of Amyotrophic lateral sclerosis (ALS) in 2028

### **3 AMYOTROPHIC LATERAL SCLEROSIS (ALS): DISEASE BACKGROUND AND OVERVIEW**

- 3.1 Introduction
- 3.2 Symptoms
- 3.3 Etiology
- 3.4 Risk Factor
- 3.5 Pathophysiology
- 3.6 Diagnosis
- 3.7 Treatment

### **4 EPIDEMIOLOGY AND PATIENT POPULATION**

- 4.1. Key Findings
- 4.2. Total Prevalent/ Incident Patient Population of Amyotrophic lateral sclerosis (ALS) in 7MM
- 4.3. Total Prevalent Patient Population of Amyotrophic lateral sclerosis (ALS) in 7MM – By Countries

### **5 EPIDEMIOLOGY OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) BY COUNTRIES (2016-2028)**

- 5.1 United States- Epidemiology (2016-2028)
  - 5.1.1 Assumptions and Rationale
  - 5.1.2 Prevalent/Incident Cases of Amyotrophic lateral sclerosis (ALS) in the United States
  - 5.1.3 Sub-Type Specific cases of Amyotrophic lateral sclerosis (ALS) in the United States
  - 5.1.4 Sex- Specific Cases of Amyotrophic lateral sclerosis (ALS) in the United States

- 5.1.5 Diagnosed Cases of Amyotrophic lateral sclerosis (ALS) in the United States
- 5.1.6 Treatable Cases of Amyotrophic lateral sclerosis (ALS) in the United States
- 5.2 EU5 Countries
  - 5.2.1 Germany
    - 5.2.1.1 Assumptions and Rationale
    - 5.2.1.2 Prevalent/Incident Cases of the of Amyotrophic lateral sclerosis (ALS) in the Germany
    - 5.2.1.3 Sub-Type Specific cases of Amyotrophic lateral sclerosis (ALS) in the Germany
    - 5.2.1.4 Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in the Germany
    - 5.2.1.5 Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in the Germany
    - 5.2.1.6 Treatable Cases of the Amyotrophic lateral sclerosis (ALS)
  - 5.2.2 France
    - 5.2.2.1 Assumptions and Rationale
    - 5.2.2.2 Prevalent/Incident Cases of the of Amyotrophic lateral sclerosis (ALS) in the France
    - 5.2.2.3 Sub-Type Specific cases of Amyotrophic lateral sclerosis (ALS) in the France
    - 5.2.2.4 Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in the France
    - 5.2.2.5 Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in the France
    - 5.2.2.6 Treatable Cases of the Amyotrophic lateral sclerosis (ALS)
  - 5.2.3 Italy
    - 5.2.3.1 Assumptions and Rationale
    - 5.2.3.2 Prevalent/Incident Cases of the of Amyotrophic lateral sclerosis (ALS) in the Italy
    - 5.2.3.3 Sub-Type Specific cases of Amyotrophic lateral sclerosis (ALS) in the Italy
    - 5.2.3.4 Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in the Italy
    - 5.2.3.5 Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in the Italy
    - 5.2.3.6 Treatable Cases of the Amyotrophic lateral sclerosis (ALS)
  - 5.2.4 Spain
    - 5.2.4.1 Assumptions and Rationale
    - 5.2.4.2 Prevalent/Incident Cases of the of Amyotrophic lateral sclerosis (ALS) in the Spain
    - 5.2.4.3 Sub-Type Specific cases of Amyotrophic lateral sclerosis (ALS) in the Spain
    - 5.2.4.4 Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in the Spain
    - 5.2.4.5 Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in the Spain
    - 5.2.4.6 Treatable Cases of the Amyotrophic lateral sclerosis (ALS)
  - 5.2.5 United Kingdom
    - 5.2.5.1 Assumptions and Rationale

5.2.5.2 Prevalent/Incident Cases of the of Amyotrophic lateral sclerosis (ALS) in the United Kingdom

5.2.5.3 Sub-Type Specific cases of Amyotrophic lateral sclerosis (ALS) in the United Kingdom

5.2.5.4 Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in the United Kingdom

5.2.5.5 Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in the United Kingdom

5.2.5.6 Treatable Cases of the Amyotrophic lateral sclerosis (ALS)  
5.3 Japan

5.3.1 Assumptions and Rationale

5.3.2 Prevalent/Incident Cases of the of Amyotrophic lateral sclerosis (ALS) in the Japan

5.3.3 Sub-Type Specific cases of Amyotrophic lateral sclerosis (ALS) in the Japan

5.3.4 Sex- Specific Cases of the Amyotrophic lateral sclerosis (ALS) in the Japan

5.3.5 Diagnosed Cases of the Amyotrophic lateral sclerosis (ALS) in the Japan

5.3.6 Treatable Cases of the Amyotrophic lateral sclerosis (ALS)

## **6 CURRENT TREATMENT & MEDICAL PRACTICES**

6.1 Treatment Algorithm

6.2 Treatment Guidelines

## **7 UNMET NEEDS**

## **8 MARKETED PRODUCT**

8.1 Drug A: Company

8.1.1 Drug Description

8.1.2 Mechanism of Action

8.1.3 Clinical Trials Details

8.1.4 Advantages & Disadvantages

8.1.5 Safety and Efficacy

8.1.6 Product Profile

8.2 Drug B: Company

8.2.1 Drug Description

8.2.2 Mechanism of Action

8.2.3 Clinical Trials Details

8.2.4 Advantages & Disadvantages

- 8.2.5 Safety and Efficacy
- 8.2.6 Product Profile
- 8.3 Drug C: Company
  - 8.3.1 Drug Description
  - 8.3.2 Mechanism of Action
  - 8.3.3 Clinical Trials Details
  - 8.3.4 Advantages & Disadvantages
  - 8.3.5 Safety and Efficacy
  - 8.3.6 Product Profile
- 8.4 Drug D: Company
  - 8.4.1 Drug Description
  - 8.4.2 Mechanism of Action
  - 8.4.3 Clinical Trials Details
  - 8.4.4 Advantages & Disadvantages
  - 8.4.5 Safety and Efficacy
  - 8.4.6 Product Profile
- 8.5 Drug E: Company
  - 8.5.1 Drug Description
  - 8.5.2 Mechanism of Action
  - 8.5.3 Clinical Trials Details
  - 8.5.4 Advantages & Disadvantages
  - 8.5.5 Safety and Efficacy
  - 8.5.6 Product Profile
- 8.6 : Company
  - 8.6.1 Drug Description
  - 8.6.2 Mechanism of Action
  - 8.6.3 Clinical Trials Details
  - 8.6.4 Advantages & Disadvantages
  - 8.6.5 Safety and Efficacy
  - 8.6.6 Product Profile
- 8.7 : Company
  - 8.7.1 Drug Description
  - 8.7.2 Mechanism of Action
  - 8.7.3 Clinical Trials Details
  - 8.7.4 Advantages & Disadvantages
  - 8.7.5 Safety and Efficacy
  - 8.7.6 Product Profile
- 8.8 : Company
  - 8.8.1 Drug Description



- 8.8.2 Mechanism of Action
- 8.8.3 Clinical Trials Details
- 8.8.4 Advantages & Disadvantages
- 8.8.5 Safety and Efficacy
- 8.8.6 Product Profile

## **9 EMERGING DRUGS**

- 9.1 Key Cross Competition
- 9.2 Emerging company
  - 9.2.1 Emerging Drug A: Company
    - 9.2.1.1 Other Development Activities
    - 9.2.1.2 Clinical Development
    - 9.2.1.3 Clinical Trials Information
    - 9.2.1.4 Safety and Efficacy
    - 9.2.1.5 Advantages and Disadvantages
    - 9.2.1.6 Product Profile
  - 9.2.2 Emerging Drug B: Company
    - 9.2.2.1 Other Development Activities
    - 9.2.2.2 Clinical Development
    - 9.2.2.3 Clinical Trials Information
    - 9.2.2.4 Safety and Efficacy
    - 9.2.2.5 Advantages and Disadvantages
    - 9.2.2.6 Product Profile
  - 9.2.3 Emerging Drug C: Company
    - 9.2.3.1 Other Development Activities
    - 9.2.3.2 Clinical Development
    - 9.2.3.3 Clinical Trials Information
    - 9.2.3.4 Safety and Efficacy
    - 9.2.3.5 Advantages and Disadvantages
    - 9.2.3.6 Product Profile
  - 9.2.4 Emerging Drug D: Company
    - 9.2.4.1 Other Development Activities
    - 9.2.4.2 Clinical Development
    - 9.2.4.3 Clinical Trials Information
    - 9.2.4.4 Safety and Efficacy
    - 9.2.4.5 Advantages and Disadvantages
    - 9.2.4.6 Product Profile
  - 9.2.5 Emerging Drug E: Company



- 9.2.5.1 Other Development Activities
- 9.2.5.2 Clinical Development
- 9.2.5.3 Clinical Trials Information
- 9.2.5.4 Safety and Efficacy
- 9.2.5.5 Advantages and Disadvantages
- 9.2.5.6 Product Profile

## **10 7MM MARKET ANALYSIS**

- 10.1 7MM Market Size of Amyotrophic lateral sclerosis (ALS)
- 10.2 7MM Percentage Share of Drugs Marketed for Amyotrophic lateral sclerosis (ALS)
- 10.3 7MM Market Sales of Amyotrophic lateral sclerosis (ALS) by Products

## **11 THE UNITED STATES MARKET OUTLOOK**

- 11.1 Market Size of Amyotrophic lateral sclerosis (ALS) in United States
- 11.2 Percentage Share of Drugs Marketed for Amyotrophic lateral sclerosis (ALS) in United States
- 11.3 Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in United States
- 11.4 Analysis of Upcoming Therapies and Impact on the Market

## **12 EU5 COUNTRIES MARKET OUTLOOK**

- 12.1 Market Size of Amyotrophic lateral sclerosis (ALS) in EU5
- 12.2 Market Size of Amyotrophic lateral sclerosis (ALS) in Germany
  - 12.2.1 Market Size of Amyotrophic lateral sclerosis (ALS) in Germany
  - 12.2.2 Percentage Share of Drugs Marketed for Amyotrophic lateral sclerosis (ALS) in Germany
  - 12.2.3 Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in Germany
  - 12.2.4 Analysis of Upcoming Therapies and Impact on the Market
- 12.3 Market Size of Amyotrophic lateral sclerosis (ALS) in France
  - 12.3.1 Market Size of Amyotrophic lateral sclerosis (ALS) in France
  - 12.3.2 Percentage Share of Drugs Marketed for Amyotrophic lateral sclerosis (ALS) in France
  - 12.3.3 Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in France
  - 12.3.4 Analysis of Upcoming Therapies and Impact on the Market
- 12.4 Market Size of Amyotrophic lateral sclerosis (ALS) in Italy
  - 12.4.1 Market Size of Amyotrophic lateral sclerosis (ALS) in Italy
  - 12.4.2 Percentage Share of Drugs Marketed for Amyotrophic lateral sclerosis (ALS) in Italy

## Italy

12.4.3 Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in Italy

12.4.4 Analysis of Upcoming Therapies and Impact on the Market

## 12.5 Market Size of Amyotrophic lateral sclerosis (ALS) in Spain

12.5.1 Market Size of Amyotrophic lateral sclerosis (ALS) in Spain

12.5.2 Percentage Share of Drugs Marketed for Amyotrophic lateral sclerosis (ALS) in Spain

12.5.3 Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in Spain

12.5.4 Analysis of Upcoming Therapies and Impact on the Market

## 12.6 Market Size of Amyotrophic lateral sclerosis (ALS) in United Kingdom

12.6.1 Market Size of Amyotrophic lateral sclerosis (ALS) in United Kingdom

12.6.2 Percentage Share of Drugs Marketed for Amyotrophic lateral sclerosis (ALS) in United Kingdom

12.6.3 Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in United Kingdom

12.6.4 Analysis of Upcoming Therapies and Impact on the Market

## 13 THE JAPAN MARKET OUTLOOK

13.1 Market Size of Amyotrophic lateral sclerosis (ALS) in Japan

13.2 Percentage Share of Drugs Marketed for Amyotrophic lateral sclerosis (ALS) in Japan

13.3 Market Sales of Amyotrophic lateral sclerosis (ALS) by Products in Japan

13.4 Analysis of Upcoming Therapies and Impact on the Market

## 14 COST ANALYSIS OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)

## 15 GENERIC COMPETITION IN AMYOTROPHIC LATERAL SCLEROSIS (ALS) MARKET

## 16 MARKET DRIVERS

## 17 MARKET BARRIERS

## 18 REPORT METHODOLOGY

18.1 Methodology/Research Approach

18.2 Data Source

18.2.1 Secondary Sources

## 18.2.2 Primary Sources

## I would like to order

Product name: Amyotrophic lateral sclerosis (ALS)- Market Insights, Epidemiology and Market Forecast 2028

Product link: <https://marketpublishers.com/r/A984411E96FEN.html>

Price: US\$ 5,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A984411E96FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

